Pharma Deal Next Pharma Completes Acquisition of Two Lonza Sites
Lonza has completed the divestment of two of its sites in Ploermel, France and Edinburgh, UK to Next Pharma. With this move, Next Pharma will be adding the two new centers to its existing manufacturing network.
Basel/Switzerland – Lonza has recently announced the completion of the divestment of its Ploermel (FR) and Edinburgh (UK) sites to Next Pharma. The agreement between both parties was previously announced on January 19, 2021.
Gordon Bates, President and Head of Small Molecules, Lonza said, “The strategic divestment of our Ploermel and Edinburgh sites will enable Next Pharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that Next Pharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”
Peter Burema, CEO of Next Pharma adds, “We are very excited at adding two new centers of excellence, at Ploermel and Edinburgh, to Next Pharma’s manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers. These technologies, combined with the know-how and expertise of the employees at both sites, will provide additional solutions for drug formulations which will benefit patients across the world. On behalf of the whole Next Pharma team, I welcome our new colleagues, and together we look forward to further develop and grow Next Pharma as a leading and well-respected European CDMO.”